Melanotan II – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Melanotan II is a cyclic version of melanotan I, more potent and shorter-acting. It produces tanning, libido enhancement, and appetite suppression through different melanocortin receptor subtypes. Used in research and unsanctioned tanning communities. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

29/100

Superseded by selective analogs on every front, with safety signals that compound the case against it as a research tool

Look, MT-II had its moment. The University of Arizona melanocortin program in the early 1990s was genuinely interesting science: a cyclic heptapeptide that simultaneously drives pigmentation and sexual response by hitting MC1 and MC4 with real affinity, plus meaningful activity at MC3 and MC5. That non-selective receptor hit profile taught us a lot about melanocortin biology. The problem is that what we learned from it was essentially: we need selective analogs. And we got them.

Every application MT-II was being studied for now has a better tool. For pigmentation and erythropoietic protoporphyria applications, afamelanotide (Scenesse) is MC1-selective, approved in both Europe and the US, backed by legitimate phase 3 data. For sexual dysfunction research, bremelanotide (PT-141, Vyleesi) hit FDA approval in 2019 as the MC4/MC3-selective successor. MT-II is the crude substrate that both of those compounds were explicitly designed to replace. Thats not a minor historical footnote; it’s the primary frame for evaluating what MT-II is good for now.

The non-selectivity is the core bench problem. If you’re studying MC4 signaling, you don’t want MC1, MC3, and MC5 activation muddying the readout. If you’re studying melanocyte biology, simultaneous cardiovascular and autonomic effects from MC3/MC4 hit complicate every endpoint. Selective tools now exist for every sub-problem MT-II was applied to, and serious mechanistic work has largely moved to them. MT-II is a blunt instrument in a field that has scalpels.

The safety signals are real and not dismissible. Case reports of melanocyte dysplasia and atypical mole development following MT-II use are in the literature. Blood pressure elevation and nausea are reliable enough adverse effects that no honest monograph omits them. None of this makes bench research impossible, but it raises the cost and the risk-management overhead of every experiment without providing a corresponding mechanistic advantage.

The evidence base itself is lopsided. The Arizona trials generated real early human data, but once afamelanotide and bremelanotide entered clinical development, the research community followed the selective analogs. What remains for MT-II is a scattered mix of older preclinical work, small uncontrolled human observations, and a large volume of gray-market anecdote that doesn’t belong in a research context. We don’t see a compelling case for prioritizing MT-II. The melanocortin system is legitimately interesting biology; if thats your program, the selective tools give you cleaner signal, better safety profiles, and actual regulatory precedent to anchor your study design.

Novelty: 22
Mechanism promise: 35
In-category differentiation: 18
Evidence quality: 35
Translational signal: 40
Research bench value: 28

Rationale MT-II’s non-selective MC1/MC3/MC4/MC5 profile was historically instructive but has since been deliberately engineered away in every downstream clinical application; afamelanotide owns the pigmentation space and bremelanotide owns the sexual function space, both with actual regulatory backing. Melanocyte dysplasia case reports and cardiovascular adverse events raise the cost of experimental use without providing any compensating mechanistic advantage over the selective tools now available.

Cyclic alpha-MSH analog

A cyclic alpha-MSH analog with both skin pigmentation and sexual response effects, sold as a research chemical with significant safety concerns.

Abstract

Melanotan II (MT-II; CAS 121062-08-6; molecular formula C50H69N15O9; molecular weight 1024.18) is a cyclic heptapeptide alpha-MSH analog developed at the University of Arizona in parallel with Melanotan I. The compound shows higher receptor affinity than the linear Melanotan I but with non-selective melanocortin receptor activity (MC1, MC3, MC4, MC5). The clinical effect profile combines the skin pigmentation of MC1 activation with the sexual response effects of MC4 activation; this dual activity led to development of the more selective bremelanotide for sexual function applications and sustained pigmentation via Melanotan I. Melanotan II is not approved by any regulatory authority and is sold as a research chemical with significant safety concerns: the non-selective receptor activity produces reliable adverse events including nausea, flushing, blood pressure elevation, and concerning case reports of melanocyte dysplasia and atypical mole development. The compound should be regarded as substantially more hazardous than the more selective marketed melanocortin agonists.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-093Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.